A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Azacitidine (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 09 May 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.